Ensysce Biosciences, Inc.
ENSC
$0.25
$0.00-1.11%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 44.38% | -85.58% | 654.35% | 331.73% | 153.15% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 44.38% | -85.58% | 654.35% | 331.73% | 153.15% |
| Cost of Revenue | -4.99% | 74.77% | 103.06% | 142.07% | 70.31% |
| Gross Profit | 30.74% | -242.45% | 27.88% | -19.57% | -45.49% |
| SG&A Expenses | -2.45% | 18.08% | 0.71% | 2.34% | -25.07% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.42% | 52.63% | 46.08% | 52.99% | 32.95% |
| Operating Income | 22.22% | -680.29% | 10.48% | -6.76% | -13.33% |
| Income Before Tax | 22.34% | -663.48% | 11.91% | 37.58% | -1.71% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 22.34% | -663.48% | 11.91% | 37.58% | -1.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -100.00% |
| Net Income | 22.35% | -663.48% | 11.91% | 37.58% | -1.74% |
| EBIT | 22.22% | -680.29% | 10.48% | -6.76% | -13.33% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 74.14% | -228.73% | 76.49% | 83.09% | 82.89% |
| Normalized Basic EPS | 74.14% | -228.74% | 76.49% | 83.09% | 82.88% |
| EPS Diluted | 74.14% | -228.73% | 76.49% | 83.09% | 82.89% |
| Normalized Diluted EPS | 74.14% | -228.74% | 76.49% | 83.09% | 82.88% |
| Average Basic Shares Outstanding | 200.24% | 337.69% | 274.67% | 269.10% | 494.63% |
| Average Diluted Shares Outstanding | 200.24% | 337.69% | 274.67% | 269.10% | 494.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |